1 October 2024 - Non-profit health plan collaborates with Fresenius Kabi and Evio Pharmacy Solutions to purchase FDA approved Humira biosimilar ...
16 October 2024 - First and only treatment approved by Health Canada for repigmentation of non-segmental vitiligo. ...
16 October 2024 - Daybue is the first and only therapy approved in Canada for the treatment of Rett syndrome, a ...
16 October 2024 - Type II variation submission based on the positive HELIOS-B Phase 3 trial in which vutrisiran significantly reduced ...
15 October 2024 - EMA submission is based on data from Phase 3 OASIS development program for elinzanetant. ...
16 October 2024 - A drug that could hold the key to delaying symptoms of devastating Alzheimer’s disease will not be ...
14 October 2024 - The EMA has published a draft agenda for this week's CHMP meeting. ...
16 October 2024 - Valneva and LimmaTech Biologics announced today that the US FDA has granted fast track designation to ...
15 October 2024 - PDUFA goal date set for 13 June 2025. ...
15 October 2024 - Galinpepimut-S currently investigated in Phase 3 REGAL trial in adult AML patients – interim analysis anticipated in ...
15 October 2024 - A Phase 1b/2a clinical trial for recurrent glioblastoma is targeted to start in late 2024/early 2025. ...
14 October 2024 - Submission is based on positive results from the pivotal Phase 3 ARANOTE trial, which showed that darolutamide ...
11 October 2024 - Version 5 of the agenda for the November 2024 PBAC meeting is now available. ...
10 October 2024 - Coherent Biopharma announced that the US FDA has granted fast track designation to CBP-1008 for injection (CBP-1008) ...
14 October 2024 - Approval based on DESTINY-Lung02 and DESTINY-Lung05 results which showed Enhertu demonstrated clinically meaningful efficacy in previously ...
14 October 2024 - The new pre-filled syringe and pre-filled auto-injector mean that patients requiring a 320 mg dose of ...